Platelet-derived growth factor (PDGF) is scientifically validated for use in oral surgery, particularly in procedures that require enhanced tissue regeneration and wound healing, such as periodontal regeneration, alveolar ridge preservation, and dental implant placement. PDGF is a potent mitogen and chemoattractant for cells critical to tissue repair, including fibroblasts and osteoblasts. Recombinant human PDGF-BB (rhPDGF-BB) is commercially available and has been approved by the FDA for certain dental and periodontal applications, often used in combination with various bone graft matrices.

Multiple randomized controlled trials and meta-analyses have demonstrated that the application of PDGF in oral surgical sites can lead to improved clinical outcomes, including greater bone formation, enhanced soft tissue healing, and improved clinical attachment levels compared to controls. For example, studies in periodontal intrabony defects and guided bone regeneration have shown statistically significant improvements in bone fill and soft tissue parameters. The mechanism of action is well-characterized: PDGF stimulates cell proliferation, migration, and angiogenesis, all essential for effective tissue regeneration.

While the evidence base is robust, some heterogeneity in study outcomes exists, and not all studies show large clinical differences between PDGF and standard care. Nonetheless, the preponderance of scientific evidence supports the use of PDGF as an adjunct in oral surgical procedures when regeneration of periodontal or alveolar tissues is desired.